I recently came across a video interview featuring Dr. Eugene Shapiro, in which he discusses a study conducted at Yale’s pediatric infectious disease clinic, which found that chronically ill children suspected of having Lyme disease were instead diagnosed with medically unexplained symptoms (MUS).
Some men are born great. Some achieve greatness. And some have greatness thrust upon them. Dr. Willy Burgdorfer at inception was a very great man and by his diligent labors achieved further greatness.
In an article entitled "Bill C-442: Shining the limelight on the Lyme-like?" published last week in the Journal of Infectious Diseases & Medical Microbiology, two Canadian physicians express both their support and reservations regarding the bill that has already passed the House of Commons. An Act Respecting a Federal Framework on Lyme Disease, introduced by Member of Parliament Elizabeth May, now awaits a second reading in the Senate. In the interim, Dr. Kevin Laupland and Dr. Louis Valiquette have shared some concerns, which are worthy of addressing.
"While we will hope for improvements in the diagnosis of Lyme disease, we are skeptical that major advances will arise as a result of Bill C-442. Accordingly, we believe that a sizable cohort of patients with chronic Lyme-like disease will remain," writes the authors.
I recently read an article in The New York Times that really spoke to me and would apply to so many of my own patients. “When the Diagnosis Is Rare, Parents May Know More Than Professionals,” by David Wheeler, highlights a family who struggles to find answers to their young child’s medical condition. For two years, the parents researched her symptoms, pursued different physicians and became her strongest advocate. Eventually, their child was diagnosed with a rare disease, Infantile Neuroaxonal Dystrophy (INAD).
The US Food and Drug Administration (FDA) is pushing to regulate (or eliminate altogether) laboratory developed tests (LDT).  Diagnostic tests for Lyme disease will be targeted, initially, as the FDA begins to phase in its oversight.
A read of the Infectious Diseases Society of America (IDSA) 2006 evidence-based guidelines would lead you to believe that for Lyme disease one size fits all. All you need is a single 200 mg dose of doxycycline for a tick bite; a single 10 to 21 days of antibiotics for Lyme disease; but no retreatment.
President Barack Obama signed an Executive Order on Thursday, September 18th which creates a task force to address concerns over the spread of drug-resistant bacteria due to an overuse of antibiotics.
ILADS evidence base treatment guidelines identified two-failed treatment protocols, a single 200 mg dose of doxycycline and a single 10 to 21 day course of antibiotic using a GRADE assessment. ILADS evidence based treatment guideline published recommendations to improve these two-failed treatment protocols.